Older patients, females, and those with comorbidities were more likely to be on multiple medications.
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
Patients were randomized to either 6 weeks of placebo first followed by 6 weeks of isosorbide mononitrate or 6 weeks of isosorbide mononitrate followed by 6 weeks of placebo.
The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.
Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.
The Food and Drug Administration (FDA) recently approved a new 60mg dosage strength for Brilinta to be used in patients with a history of MI beyond the first year.
New Haven Pharmaceuticals announced new data that demonstrates Durlaza (aspirin) extended-release capsules provide sustained antiplatelet control for a full 24-hour period in high-risk patients.
Jardiance, a sodium-glucose co-transporter 2 inhibitor, is indicated as adjunct to diet and exercise to improve glycemic control in adults with T2D.
Results showed that approximately 74% of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent to their standard-of-care.